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ABSTRACT
Somatostatin receptors are a pivotal target for treatment of pancreatic 
neuroendocrine tumors (pNET), either with somatostatin analogues (SSA) or 
radiolabeled SSA. The highest affinity target for the most commonly used SSA is 
the somatostatin receptor type 2 (sst2). An important factor that may complicate 
treatment efficacy, is the variable number of receptors expressed on pNETs. Gene 
expression is subject to complex regulation, in which epigenetics has a central role. In 
this study we explored the possible role of epigenetic modifications in the variations 
in sst2 expression levels in two human pNET cell lines, BON-1 and QGP-1. We found 
upregulation of sst2 mRNA after treatment with the epidrugs 5-aza-2’-deoxycytidine 
(5-aza-dC) and valproic acid (VPA), an increased uptake of radiolabeled octreotide, 
as well as increased sensitivity to the SSA octreotide in functional cAMP inhibition. 
At epigenetic level we observed low methylation levels of the sst2 gene promoter 
region irrespective of expression. Activating histone mark H3K9Ac can be regulated 
with epidrug treatment, with an angle of effect corresponding to the effect on mRNA 
expression. Repressive histone mark H3K27me3 is not regulated by either 5-aza-dC 
or VPA. We conclude that epidrug treatment, in particular with combined 5-aza-dC 
and VPA treatment, might hold promise for improving and adding to current SSA 
treatment strategies of patients with pNETs.
INTRODUCTION
Pancreatic neuroendocrine tumors (pNET) can 
be divided into two categories, e.g. functioning and 
nonfunctioning. Functioning tumors, e.g. insulinoma 
and glucagonoma, overexpress pancreatic hormones, 
which may lead to devastating paraneoplastic syndromes. 
Nonfunctioning tumors, which are the majority of pNETs, 
have neuroendocrine histology, however no hormonal 
syndrome associated with hypersecretion.
A primary target for medical treatment of pNETs 
is the somatostatin receptor (SSTR) type 2(sst2) [1]. The 
primary goal of sst2 targeted treatment is the control 
of excessive hormone secretion by functional tumors. 
Furthermore, the role of SSAs in the control and/or 
reduction of tumor progression has been studied in 
recent years. Two randomized double blind placebo 
controlled studies (PROMID and CLARINET) showed a 
growth reducing effect of both long acting octreotide and 
-lanreotide on midgut and pancreatic NETs [2, 3].
An additional important class of analogues is the 
radiolabeled SSAs. Radiolabeled SSAs are of significant 
importance for tumor imaging, localization and diagnosis 
[4]. In addition, they are used for peptide receptor 
radionuclide therapy (PRRT), an important treatment 
option for pNETs, particularly in inoperable and/or 
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metastasized tumors [5]. Sufficient uptake levels of 
radiolabeled SSAs are essential and a higher uptake leads 
to a higher remission rate. As such, the number of SSTR 
expressed on the tumor cell may be important for the 
efficiency of treatment. High uptake on the pretreatment 
octreoscan is thus crucial for treatment outcome, next 
to high patient performance [5]. Moreover, it has been 
described that neoadjuvant treatment with PRRT could 
increase the number of patients eligible for surgery, as 
adjuvant treatment may decrease the chance of tumor 
spread following surgery or reduces growth of already 
present micrometastases [6].
Sst2 as being the SSTR to which octreotide and 
lanreotide bind with the highest affinity, makes this 
receptor the most important target receptor for treatment 
efficacy [7]. Okuwaki et al. showed the relationship 
between sst2 protein expression and survival in pNET 
patients [8]. This study also shows that sst2 expression 
is not present or not equally high in every pNET, 
limiting treatment options for patients with very low or 
no expression. To the best of our knowledge, no DNA 
mutations have been found in the sst2 gene that could 
account for low protein levels in a number of the patients.
Cells have various mechanisms to regulate gene 
expression, one of which is epigenetic regulation. 
Epigenetics comprises various modes of gene expression 
management that can interfere with transcription factors 
targeting gene promoters. Modifications to the epigenome, 
that include CpG island methylation and a wide range 
of histone modifications, impact on and can modulate 
gene expression. Alterations in the epigenetic regulatory 
system of a cell may also play a major role in cancer 
development and progression. Despite a gene being free of 
mutations, several epigenetic alterations can turn off tumor 
suppressor genes or turn on oncogenes, e.g. by chromatin 
condensation or hypermethylation of CpG islands in the 
promoter regions.
Because of the pliable nature of epigenetic 
modifications, it is possible to induce changes chemically. 
In recent years several drugs have been exploited that 
can reverse CpG methylation and others that inhibit 
histone de-acetylation. Two of these so-called epidrugs 
are the DNA methyltransferase inhibitor (DNMTi) 5-aza-
2'-deoxycytidine (5-aza-dC) and histone deacetylase 
inhibitor (HDACi) valproic acid (VPA).
Torrisani et al. identified a novel transcription 
start site (tss) in sst2, upstream from the first described 
transcription start site by Petersenn et al. in 1999 [9, 
10]. CpG methylation levels around the upstream tss are 
inversely associated with mRNA expression levels in 
several cell lines. In the investigated panel of cell lines it 
was found that epidrug treatment significantly increased 
sst2 expression in cell lines with low base line expression. 
Recently, Sun et al. described that VPA inhibited growth 
of BON-1 cells [11]. In their studies, VPA treatment 
induced cell cycle arrest as well as apoptosis. Furthermore, 
Greenblatt et al. previously showed that BON-1 cell 
xenografts in mice treated with VPA grow at a slower rate 
than in control mice [12].
In order to determine whether epigenetic 
mechanisms may be involved in the functional expression 
of sst2 in pNET cells, we studied two well characterized 
pNET cell line models, BON-1 and QGP-1 [13-15]. We 
present data on the expression and functionality of sst2 in 
untreated cells, as wells as in cells after treatment with 
the epidrugs 5-aza-dC and VPA. We studied whether 
epigenetic changes and regulation could be responsible 
for variations in sst2 expression and functionality. The 
effect of 5-aza-dC and VPA on sst2 expression, on uptake 
of radiolabeled sst2-preferring SSA, cAMP signaling, 
promoter CpG methylation, as well as enrichment of 
activating histone mark H3K9Ac and repressive histone 
mark H3K27me3 is reported. The ultimate future goal 
is being able to increase sst2 expression and/or signaling 
in pNET patients, in order to improve response to- and 
optimize the effect of SSA treatment and PRRT.
RESULTS
SSTR subtype mRNA expression
In BON-1 cells sst1 (1.3 ± 0.31; mean ± SEM) 
is expressed at the highest level relative to sst5 (0.31 ± 
0.062) and sst2 (0.087 ± 0.013). Sst3 levels were very low 
(0.011 ± 0.0030) (Figure 1A). Compared to BON-1 cells, 
expression levels are generally low in QGP-1, with highest 
expression of sst2 (0.066 ± 0.0096), followed by sst1 
(0.059 ± 0.0084) and sst5 (0.027 ± 0.0019). Sst3 expression 
is not detectable in QGP-1 cells (Figure 1B). Because in 
pNET treatment sst2 is the most important target receptor 
for SSAs like octreotide and lanreotide, we focused in the 
remaining part of our studies on this receptor subtype. For 
both cell lines EC50 concentrations for inhibition of cell 
growth were determined for 5-aza-dC and VPA. In BON-
1 and QGP-1 EC50 values for 5-aza-dC were 100 nM and 
50 nM, respectively. For VPA, the EC50 values were 2.5 
mM in BON-1 and 1 mM in QGP-1 (data not shown). 
Cells were cultured in the absence or presence of EC50 
concentrations of either 5-aza-dC, VPA or the combination 
of both drugs for 7 days. The two cell lines responded 
differentially to treatment with these drugs with respect 
to sst2 mRNA expression. In BON-1, 5-aza-dC and VPA 
alone significantly increase sst2 expression by 255 and 
145 %, respectively. Furthermore, the combined treatment 
with 5-aza-dC and VPA enhanced expression by 770% 
(Figure 1C). In QGP-1 cells, 5-aza-dC alone stimulated 
sst2 expression by 635%, while VPA inhibited receptor 
expression by 60%. In addition, VPA also attenuated the 
stimulatory effect of 5-aza-dC in combined treatment to 
160% stimulation (Figure 1D). Sst1, sst3 and sst5 mRNA 
expression results for epi-drug treatment in both cell lines 
can be found in the Supplementary Figure 1. For both cell 
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lines, the changes in receptor expression of sst1, sst3 and 
sst5 with epidrug treatment, are minimal compared to the 
changes in sst2.
Somatostatin receptor uptake
Figure 2 shows the effect of epidrug pretreatment 
on the uptake (internalization) of the sst2 preferring 
SSA [125I-Tyr3]octreotide. In the BON-1 cell line, 5-aza-
dC increased uptake of [125I-Tyr3]octreotide by 185% 
and VPA by 595%. The combined treatment with EC50 
concentrations of 5-aza-dC and VPA significantly 
increased the uptake of [125I-Tyr3]octreotide with 3820% 
(Figure 2A). In QGP-1 the effects of epidrug treatment 
are all stimulatory, although a statistically significant 
stimulation was observed only in cells that were treated 
with the combination of the drugs. Combined treatment 
with 5-aza-dC and VPA resulted in a statistically 
significant increased uptake of [125I-Tyr3]octreotide by 
300% (Figure 2B).
Effect on cAMP production
In order to evaluate whether epidrug treatment 
also could induce changes in the ability of the pNET 
cell lines to respond functionally to SSA treatment, we 
measured the effect of octreotide on forskolin-stimulated 
cAMP production in control and epidrug pretreated cells. 
Treatment of BON-1 cells with 5-aza-dC lowered the 
EC50 for the inhibitory effect of octreotide treatment on 
cAMP levels from 60 nM in untreated control cells to 
18 nM in 5-aza-dC treated cells, indicating an enhanced 
effect of octreotide treatment at the level of cAMP 
inhibition (Figure 3A, 3B), although this difference did 
not reach statistical significance. VPA treatment did not 
explicitly influence the EC50 concentration (65 nM; Figure 
3C), while the combined treatment further reduced the 
inhibitory EC50 concentration of octreotide significantly 
to 1 nM (p < 0.001 compared to control) (Figure 3D).
In QGP-1 cells, we found a reverse effect of octreotide 
on forskolin-stimulated cAMP production. The response 
Figure 1: Ssts mRNA expression levels. Mean expression levels ± SEM of ssts in BON-1 cells (n=2) A and QGP-1 cells (n=3) B, 
C. effect of treatment with 5-aza-dC (100 nM), VPA (2.5 mM) or the combination of both drugs on sst2 expression in BON-1 cells, D. 
effect of treatment with 5-aza-dC (50 nM), VPA (1 mM) or the combination of both drugs on sst2 expression in QGP-1 cells. Data are the 
mean ± SEM and expressed as the percentage of untreated control cells. The expression levels were normalized to housekeeping gene hprt. 
**p<0.01, ***p<0.001, ND: not detectable.
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to octreotide in the untreated QGP-1 cells did not show a 
dose dependent reduction in cAMP levels, but instead a 
stimulatory effect, with an EC50 of 130 nM in untreated 
cells (Figure 3E). The EC50 was reduced to only 0.36 nM in 
5-aza-dC treated cells (Figure 3F), while VPA reduced EC50 
to 37 nM and additionally lowered the maximal stimulation 
(Figure 3G). Combined treatment slightly increased the 
EC50 to 250 nM, and also lowered the maximal stimulation 
(Figure 3H). None reached statistical significance.
DNA methylation
To determine the role of DNA methylation in sst2 
regulation, methylation was quantitatively evaluated by 
pyrosequencing. The CpG sites studied were based on the 
work of Torrisani et al [9], who determined a number of 
CpG positions essential in the regulation of sst2 mRNA 
expression. These CpG positions are located in the 
promoter region, around the transcription start site. In both 
BON-1 cells and QGP-1 cells methylation levels were 
found to be low, all positions had under 10% methylation 
(Figure 4A and 4B). To verify the data, controls with high 
and low methylated DNA were sequenced in parallel as a 
positive and negative control. Figure 4C shows measured 
methylation levels between 85 and 96% and 2 and 7%, 
respectively, validating the pyrosequencing data in BON-1 
and QGP-1 cells.
Histone modification
To assess the role of the histone code in the 
regulation of sst2 expression, we evaluated the presence 
of two marks in untreated cells and the change of these 
marks under the influence of epi-drug treatment. By 
means of chromatin immunoprecipitation (ChIP) we 
determined enrichment of the promoter region of sst2 for 
active transcription mark H3K9Ac and for the repressive 
transcription mark H3K27me3.
Enrichment was determined at three positions 
in the sst2 promoter; at the transcription start site as 
described by Torrisani et al. and at two positions prior 
to this transcription start site [9]. Both modifications 
were detected in cell lines BON-1 and QGP-1. In BON-
1 cells, individual 5-aza-dC and VPA treatment lead to 
a slight increase of activating histone mark H3K9Ac on 
all three positions, although this does not reach statistical 
significance, except for VPA treatment at position -2 
(Figure 5A). The drugs combined gave no significant 
change (Figure 5A). No statistically significant effect 
of 5-aza-dC was observed on repressive histone mark 
H3K27me3 at either of the positions, while VPA showed a 
trend to increased enrichment at positions -2 and -1, which 
did not reach statistical significance, however (Figure 5B). 
H3K9Ac enrichment in QGP-1 cells is not influenced by 
VPA or combined treatment, while 5-aza-dC induces 
a statistically significant increase of the modification at 
position -1 relative to the tss (Figure 5C). Repressing 
histone mark H3K27me3 is in QGP-1 cells not influenced 
by either of the treatments relative to control (Figure 5D). 
In all experiments, efficiency was tested and confirmed 
with negative and positive control primers (data not 
shown).
DISCUSSION
Sst2 is the highest affinity receptor for the 
conventional SSAs used in clinical setting, e.g. octreotide 
and lanreotide [7]. Expression of sst2 is highly variable 
Figure 2: Uptake of radiolabeled [125I-Tyr3]octreotide. Specific uptake of radiolabeled [125I-Tyr3]octreotide by BON-1 (n=3) and 
QGP-1 cells (n=3), without and with treatment with 5-aza-dC (BON-1: 100 nM, QGP-1: 50 nM), VPA (BON-1: 2.5 mM, QGP-1: 1 mM), or 
their combination. Specific uptake was calculated as the difference between total uptake and the uptake in the presence of excess unlabeled 
octreotide. Values were corrected for differences in cell number as measured by the DNA content per well. Values are expressed as the 
percentage of untreated control. A. BON-1, B. QGP-1. *p<0.05 ***p<0.001. Specific uptake values for control BON-1 cells amounted 0.14 
± 0.017% (mean ± SEM) and for QGP-1 0.11 ± 0.051% of added dose.
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between pNET patients [8, 16-19], where higher 
expression of sst2 is associated with better treatment 
results and better survival [5, 8]. The ability to upregulate 
sst2 expression in pNETs could improve treatment efficacy.
Epigenetic mechanisms play a key role in the 
regulation of gene expression [20]. DNMTs, HDACs and 
histone acetylases are some of the components involved 
in chromatin remodeling and, therefore, gene expression 
[21, 22]. We chose to work with two epidrugs, capable 
of altering epigenetic marks and which are already being 
used clinically; the DNMTi 5-aza-dC and the HDACi 
VPA. We determined the EC50 for both drugs in both 
cell lines, based on their inhibitory effect on cell growth. 
The determined concentrations are clinically feasible. 
Figure 3: Octreotide-induced inhibition of forskolin-stimulated cAMP production. Octreotide-induced inhibition of 
forskolin-stimulated cAMP production in BON-1 A-D. (n=3) and QGP-1 E-H. cells (n=3), without or with treatment with 5-aza-dC (BON-
1: 100 nM, QGP-1: 50 nM), VPA (BON-1 2.5 mM, QGP-1: 1 mM), or their combination.
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Figure 4: Sst2 promoter methylation. Percentage sst2 promoter methylation of CpG positions surrounding the proximal transcription 
start site in A. BON-1 cells (n=3), B. QGP-1 cells (n=3) and C. high and low methylated control DNA (all mean ± SEM). The transcription 
start site is located between -1 and 1.
Figure 5: ChIP of histone marks H3K9Ac and H3K27me3 for the sst2 promoter. Enrichment of the sst2 promoter as determined 
by ChIP for histone marks H3K9Ac and H3K27me3 (mean ± SEM) in BON-1 and QGP-1 cells, without or with treatment with 5-aza-dC 
(BON-1: 100 nM, QGP-1 50 nM), VPA (BON-1: 2.5 mM, QGP-1: 1 mM), or their combination. A. H3K9Ac in BON-1 cells (n=2) B. 
H3K27me3 in BON-1 cells (n=3) C. H3K9Ac in QGP-1 cells (n=2) D. H3K27me3 in QGP-1 cells (n=3). *p<0.05 vs untreated control.
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Plasma concentrations that are reached for 5-aza-dC in 
hematological malignancies and solid tumors range from 
0.04 μM to 5.6 μM and were reached using different 
treatment schedules [23, 24]. The EC50 concentrations 
of 100 nM in BON-1 cells and 50 nM in QGP-1 cells 
are within this range. The EC50 concentrations for VPA 
determined in both cell lines, 2.5 mM in BON-1 cells 
and 1 mM in QGP-1 cells, are close to therapeutically 
achievable serum concentrations, which range from 0.3 
mM to 1 mM [25, 26].
The effect of 5-aza-dC and VPA on sst2 mRNA 
expression levels differed between the cell lines. In both 
cell lines 5-aza-dC stimulates expression, but in QGP-1 
two times more efficiently. In contrast, VPA increases 
sst2 expression in BON-1, but is inhibitory in QGP-1. 
Moreover, while the effect of combined treatment leads 
to a considerably enhanced expression of sst2 in BON-
1 cells, VPA negatively interferes with the stimulating 
effect of 5-aza-dC in QGP-1, as expected from the effect 
of VPA alone in this pNET cell line. The increase in sst2 
expression induced by VPA treatment of BON-1 cells is in 
agreement with previous observations by Sun et al. [11].
In order to demonstrate the effect of epidrug 
treatment on the uptake of the radiolabeled sst2 preferring 
SSA octreotide, sst2 internalization studies were 
performed. In BON-1, 5-aza-dC and VPA treatment 
increased the uptake of [125I-Tyr3]octreotide significantly. 
Combined treatment significantly increases uptake by 
nearly 40-fold, consolidating the enhanced effect of both 
drugs seen on sst2 mRNA expression. Unlike the effect 
on mRNA expression, VPA stimulates uptake more than 
5-aza-dC in BON-1.
While there was an inhibitory effect of VPA in QGP-1 
on sst2 mRNA expression, uptake of [
125I-Tyr3]octreotide was 
increased in VPA treated cells, as well as following 5-aza-
dC treatment. Combined treatment induced a statistically 
significant increased uptake, which was higher than each 
compound individually, albeit not fully additive. Increased 
uptake does not necessarily need to be the result of increased 
numbers of sst2 on the cellular membrane. An increase in 
turnover and redirection of the receptor to the membrane 
might also cause a higher amount of internalized [125I-Tyr3]
octreotide [27]. The results of the internalization studies 
show that, if these data can be extrapolated to the in vivo 
situation, both compounds, and particularly the combination, 
could have a potential role in improving treatment efficiency 
of PRRT in patients with pNETs.
To further confirm the functional outcome of the epi-
drugs, we determined the effect of treatment on the efficacy 
of octreotide to inhibit cAMP production. Inhibition of 
cAMP is one of the main mechanisms via which sst2 
activation results in inhibition of hormone release.
Octreotide inhibited forskolin-stimulated cAMP 
production in BON-1 cells with an EC50 of 60 nM, which 
was markedly decreased by 5-aza-dC treatment, to 18 nM. 
While VPA treatment had no distinct effect, leaving the 
EC50 at 65 nM, combined treatment enhances octreotide 
sensitivity even more than 5-aza-dC alone, to an effective 
EC50 dose of 1 nM. These data suggest a shift in the potency 
of octreotide to inhibit cAMP production to a more sst2-like 
(IC50 0.38-0.60 nM) binding profile [7]. These data show that 
5-aza-dC could play a major role in increasing sensitivity to 
treatment with sst2-preferring SSA, most likely by inducing 
an upregulation of sst2, and even more when combined 
with VPA. In untreated QGP-1 cells, octreotide treatment 
does not lead to inhibition of cAMP production, but instead 
increases cAMP expression with an EC50 of 130 nM. Pre-
treatment with 5-aza-dC considerably reduces the EC50 dose 
to 0.36 nM, and although the angle of the effect remains 
an increase of cAMP production, 5-aza-dC did reduce the 
EC50 of octreotide to a clinically relevant concentration. Also 
VPA treatment and combined treatment increased cAMP 
production, but in line with the reduced sst2-expression, 
VPA alone, as well as combined VPA/5-aza-dC treatment 
lowered the maximal response to octreotide. To the best of 
our knowledge increased cAMP production upon SSTR 
activation has been previously described only in porcine 
somatotroph cells [28]. Currently, it is unclear whether this 
process can be found in tumors of patients, and whether this 
could play a role in sensitivity to treatment. This remains to 
be investigated.
Considering the variable sst2 expression levels in 
pNETs [8, 16-19], and the absence of known mutations, 
epigenetic modifications of sst2 regulatory elements 
might explain these differences between patients. By 
pyrosequencing we analyzed 8 CpGs present in the 
promoter region of the sst2 gene, which previously have 
been shown to be regulating sst2 expression [9]. In both 
BON-1 and QGP-1 low methylation levels were detected, 
around only 3% in BON-1 and 2% in QGP-1. These low 
levels suggest that CpG hypermethylation in this region 
does not play a role in low sst2 expression or loss of 
expression, although a role of CpG methylation in other 
regions of the sst2 gene cannot be excluded.
Epigenetics, however, comprise a wide range 
of modifications, such as a large series of histone 
modifications, controlling chromatin accessibility. Two 
well-known histone marks, H3K27me3, associated with 
transcriptional repression, and H3K9Ac, associated 
with active gene transcription were studied. In BON-
1, both 5-aza-dC and VPA induced a slight increase in 
enrichment of active transcription mark H3K9Ac at all 
three studied positions, although this effect was only 
significant for VPA treatment at position -2. The general 
direction of the effect of treatment with 5-aza-dC and 
VPA on sst2 mRNA expression is reflected in the effect 
on enrichment of histone marks H3K9Ac in BON-1 
cells. The effect on H3K27me3 is contradictory, as the 
expected effect is downregulation, whereas an (non-
significant) upregulation is seen after treatment with VPA 
and the combination. Similar observations were made 
in QGP-1 cells. The absence of an effect of 5-aza-dC on 
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H3K27me3, in combination with an increase in H3K9Ac 
in QGP-1, although not significant, is more in line with 
the observed increased sst2 expression. In conclusion, 
H3K27me3 appears thus to be a histone mark that does not 
play a major role in regulation of the sst2 promoter, while 
H3K9Ac does seem to play a role in activation of sst2 and 
is a good candidate for further studies.
As the treatment with epidrugs in our models is 
not selective in targeting genes, it cannot be excluded 
that indirect regulation of sst2 expression takes place. 
Transcription factors and other regulating factors might 
be upregulated or redirected, leading to increased mRNA 
expression. In addition, second messenger pathway 
participants might be influenced, or recycling of the 
receptor could be slowed, leading to enhanced functional 
response.
Currently, epidrugs have limited use in cancer 
treatment. Based on the results of this study, and the 
clinical trials performed so far with either 5-aza-dC or VPA 
or their combination [29, 30], these epidrugs alone or in 
combination, and with concomitant treatment with SSA, 
may be a future treatment approach in pNET patients that are 
otherwise not responding to- or suitable for any treatment.
In conclusion, the results of our study show that 
epidrug treatment, in particular with 5-aza-dC and VPA, 
might hold promise for improving current treatment 
strategies for patients with pNET with different types of 
SSA, in particular in patients with difficult to treat pNETs 
with low sst2 numbers. However, further experiments are 
needed to validate whether a similar upregulation of sst2 
expression and sst2 functionality can be achieved in vivo.
MATERIALS AND METHODS
Cell culture
In this study two human pNET cell lines were 
used, BON-1 [13] and QGP-1 [14]. BON-1 cells were 
a kind gift from Dr. Townsend (University of Texas 
Medical branch, Galveston, USA). QGP-1 cells were 
purchased from the Japanese Collection of Research 
Bioresources Cell Bank (JRCB, Osaka, Japan). Both 
cell lines were confirmed as mycoplasm-free. Using 
short tandem repeat profiling the identity of the BON-1 
and QGP-1 cell lines was confirmed [15]. BON-1 cells 
were cultured in DMEM-F12 supplemented with FCS 
(10% v/v) L-glutamine (2 mmol/L), fungizone (0.5 mg/L) 
and penicillin (1 × 105 u/L). QGP-1 cells were cultured 
in RPMI-1640 supplemented with FCS (10% v/v) and 
penicillin (1 × 105 u/L). Cells were cultured in 75 cm2 
culture flasks (Corning Life Sciences B.V., Amsterdam, the 
Netherlands) at 37°C in a 5% CO2 humidified incubator 
and passaged by trypsinization every 7 days, with medium 
supplementation on the fourth day, until a maximum of 
20 passages. For experiments cells were harvested with 
trypsin (0.05%)-EDTA (0.53 mM) and plated in 12 or 
24 well plates (Greiner Bio-one B.V., Alphen aan den 
Rijn, the Netherlands). All media and supplements were 
obtained from Gibco (Life Technologies, Bleiswijk, the 
Netherlands) except for penicillin (Astellas Pharma B.V. 
Leiden, the Netherlands).
Compounds
VPA sodium salt and 5-aza-dC powder were 
purchased from Sigma-Aldrich (Zwijndrecht, the 
Netherlands). VPA sodium salt was stored at -20°C and 
freshly prepared by dissolving in culture medium prior to 
each experiment and compound refreshing. 5-aza-dC was 
dissolved in H2O at a concentration of 10
-3 M, aliquoted 
and stored at -20°C.
Cell proliferation assay
To determine the optimal cell number for the culture 
of the cell lines in 24 well plates and determination of the 
EC50 concentrations for 5-aza-dC and VPA treatment, 
DNA measurement (as a measure of cell number) was 
performed. Cells were cultured and, in case of EC50 
determination, treated in 24 well plates. Medium and 
compounds were refreshed after three days. After 7 days of 
treatment the medium was removed and cells were lysed 
with 150 μl ammonia solution (1 mol/L)-Triton-X100 
(0.2% v/v) per well and incubated 10 minutes at 4°C. 
Plates were sonicated 5 seconds per well at an amplitude 
of 1400 microns to shear the DNA, and incubated for 
another 10 minutes at 4°C. Per well 1 ml assaybuffer (100 
mmol/L NaCl, 10 mmol/L EDTA, 10 mmol/L Tris; pH 
7.0) was added. Per well 20 μl was pipetted into a cell 
star plate, 96 wells (Greiner), along with a standard curve 
of calf thymus DNA (Sigma) and 200 μl Hoechst 33258 
(Sigma-Aldrich). Measurement was performed at 350 and 
455 nm excitation and emission wavelengths respectively 
on a Victor X4 plate reader (Perkin Elmer, Waltham, 
Massachusetts, USA) and counts were referenced against 
the standard curve.
Quantitative RT-PCR
Quantitative RT-PCR was performed according to 
a method previously described [31, 32]. In brief, poly 
A+ mRNA was isolated from cells using Dynabeads 
oligo(dT)25 (Invitrogen Dynal AS, Oslo, Norway). The 
mRNA was eluted from the beads with 2 times 23 μl 
H2O incubated 2 minutes at 65°C. Subsequently cDNA 
was synthesized with twice 20 μl, once with Reverse 
Transcriptase and once without. The cDNA is diluted five 
times, Q-PCR was done on 5 μl sample with Taqman® 
Universal PCR mastermix (Applied Biosystems, Life 
Technologies) and detection using an ABI Prism 7900ht 
sequence detection system (Applied Biosystems). Primer 
and probe sequences are shown in Table 1.
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Table 1: Primer-probe sequences for Q-RT-PCR, PCR and sequencing primer sequences for pyrosequencing (Btn: 
biotin) and qPCR primer sequences for ChIP.
cDNA primers Sequence
hprt
 Forward CAC TGG CAA AAC AAT GCA GAC T
 Reverse GTC TGG CTT ATA TCC AAC ACT TCG T
 Probe CAA GCT TGC GAC CTT GAC CAT CTT TGG A
sst1
 Forward CAC CGT GGC CAA GGT AGT AAA
 Reverse CCA CGA TGG GCA GGA TGA
 Probe CTG GGC GTG TGG GTG CTA TCG C
sst2
 Forward TCG GCC AAG TGG AGG AGA C
 Reverse AGA GAC TCC CCA CAC AGC CA
 Probe CCG GAC GGC CAA GAT GAT CAC C
sst3
 Forward CTG GGT AAC TCG CTG GTC ATC TA
 Reverse AGC GCC AGG TTG AGG CTG TA
 Probe CGG CCA GCC CTT CAG TCA CCA AC
sst5
 Forward CAT CCT CTC CTA CGC CAA CAG
 Reverse GGA AGC TCT GGC GGA AGT T
 Probe CCC GTC CTC TAC GGC TTC CTC TCT GA
Pyrosequencing primers sequence
PCR
 Forward [Btn]GGG TTG GTT GGG TTA GTT TT
 Reverse ATT CCT AAC TCC TCC ACC CTC TT
Sequencing
 Reverse strand ACC TCA AAC TAA AAC TCT A
ChIP primers sequence
-2
 Forward TGC TGA CTG ACG TGG CTA CA
 Reverse CGC ACC TGG AGT CCA AGA TT
-1
 Forward GTC CTT GCC ATG AGT CTT GA
 Reverse CAG GCA GAG CTT ACA GAC AG
tss
 Forward AGC GAA GCC GCT GTG ACG TA
 Reverse TCT GGG CGC TGG TGG TCT TG
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Somatostatin receptor uptake
SSTR internalization studies were performed as 
previously described with minor adjustments [33]. In 
short, cells of either cell line, BON-1 and QGP-1, were 
seeded in 75 cm2 culture flasks in 10 ml regular culture 
medium on day 0. On day 1, four conditions were 
initiated; control, 5-aza-dC (BON-1: EC50 100 nM, QGP-
1: EC50 50 nM); VPA (BON-1: EC50 2.5 mM, QGP-1: 
EC50 1 mM); and combined 5-aza-dC and VPA treatment. 
Supplemental medium and compounds were added on 
day 3. On day 6, the cells are trypsinized and plated in 12 
well plates (1 · 106 cells per well), 6 wells per treatment 
for triplicate incubation with either [125I-Tyr3]octreotide 
or [125I-Tyr3]octreotide and excess unlabeled octreotide to 
block internalization. On day 8, cells were washed twice 
with internalization medium (DMEM supplemented with 
HEPES (30 mM) (Sigma-Aldrich)), L-Glutamine (2 mM), 
sodium pyruvate (1 mM) (Gibco), penicillin (105 U/L), 
fungizone (0.5 mg/L) and 0.2% BSA (Sigma-Aldrich) 
(pH 7.4). Subsequently, 1 ml of internalization medium 
per well was added to the cells, as well as 200,000 counts 
[125I-Tyr3]octreotide (final concentration ~0.1 nM) was 
added to the wells and the plates were incubated at 37°C 
for 4 hours with or without excess unlabeled octreotide. 
After incubation the cells were washed twice with ice-
chilled internalization medium. Low pH treatment with 
1 ml sodium acetate (20 mM) (Sigma-Aldrich) in Hanks 
Balanced salt solution (Gibco), pH 5.0 (HBSS-Ac) was 
used to collect the membrane bound fraction of [125I-Tyr3]
octreotide. The cells were incubated for 10 minutes 
at 37°C, subsequently the supernatant was collected 
(membrane fraction 1) and cells were washed one 
additional time with HBSS-Ac and supernatant collected 
(membrane fraction 2, membrane fraction data not 
shown). Finally, the cells were extracted with 1 M NaOH, 
representing the internalized fraction of radioactivity. By 
Riastar (Perkin Elmer) internalized counts per million 
were determined in each treatment condition and fraction.
Effect on cAMP production
Cells were plated in 75 cm2 culture flasks and left to 
adhere for 2 days. Subsequently the cells were pretreated 
with no compound (vehicle); 5-aza-dC; (BON-1: EC50 100 
nM, QGP-1: EC50 50 nM); VPA (BON-1: EC50 2.5 mM, 
QGP-1: EC50 1 mM); or 5-aza-dC and VPA combination 
for 5 days. After 5 days of incubation with drugs, the 
cells were trypsinized and plated in a 24 well plate (0.1 
· 106 cells per well) without or with compounds for an 
additional 2 days. After 2 days (total drug treatment period 
7 days), the cells were incubated in triplicate without or 
with forskolin (10-6 M; Sigma-Aldrich) or with forskolin 
plus increasing concentrations of octreotide (range 10-6-10-
10 M; Sandostatin, Novartis, Arnhem, the Netherlands) for 
30 minutes in a CO2 incubator at 37°C. The supernatant 
of the cells was collected, snap frozen on dry ice and 
stored at -80°C. cAMP levels were measured with RIA 
(Beckman Coulter, Woerden, the Netherlands) according 
to manufacturer’s protocol.
DNA isolation, bisulfite treatment and 
pyrosequencing
DNA was isolated from untreated- and 5-aza-dC; 
(BON-1: EC50 100 nM, QGP-1: EC50 50 nM) treated 
BON-1 and QGP-1 cells, according to protocol with the 
Genome Wizard DNA isolation kit (Promega Corporation, 
Madison, USA). For bisulfite conversion 1000 ng input 
DNA was used with the Zymo Research EZ DNA Zymo 
kit according to manufacturer’s protocol (Zymo Research 
Corporation, Irvine, USA). Primer design was done 
with PyroMark Assay Design 2.0 (Qiagen N.V., Venlo, 
the Netherlands). Bisulfite treated DNA was aliquoted 
and stored at -20°C. PCR of bisulfite treated DNA was 
performed with the primers listed in Table 1 and with the 
following program: 5 minutes 95°C, 45 cycles 30 seconds 
95°C - 30 seconds 60°C – 30 seconds 72°C, 1 cycle 10 
minutes 72°C, ∞ 4°C. PCR products were analyzed on 
the PyroMark Q24 (Qiagen) with PyroMark Gold Q24 
reagents (Qiagen) according to manufacturer’s protocol
Chromatin isolation
Chromatin isolation was performed to evaluate 
H3K9Ac and H3K27me3 enrichment. BON-1 and QGP-
1 cells were plated on day 1 and grown until day 4, after 
which the medium was changed and 5-aza-dC (BON-1 
EC50 100 nM, QGP-1 EC50 50 nM); VPA (BON-1 EC50 
2.5 mM, QGP-1 EC50 1 mM); and the combination of 
both drugs were added, except to the control flasks. The 
cells were incubated for 4 days and harvested on day 8. 
The cells were trypsinized and centrifuged to remove the 
trypsin. Cells from the same treatment condition were 
resuspended and pooled in 15 ml fresh medium in a 50 
ml tube. Formaldehyde was added to a final concentration 
of 1% to cross-link, and incubated rotating at room 
temperature for 10 minutes. Subsequently 2.5 M glycine 
was added to a final concentration of 0.125 M to quench 
the reaction. The fixed cells were then centrifuged at 
4°C, 5 minutes at 1500 rpm and washed twice with ice-
cold PBS. The cells were resuspended in 750 μl PBS and 
transferred to a 1.5 ml tube and centrifuged at 4°C for 5 
minutes at 3000 rpm. Cells were incubated 10 minutes 
in 500 μl nucleic lysis buffer (1% SDS + 50 mM Tris-
HCL (pH8.1) + 10 mM EDTA (pH8.0) with PMSF on ice. 
Following incubation the lysates were sheared (cooled on 
ice), with a mean of 7 times 20 second pulses with 60 
second pauses to cool. Samples were centrifuged at 4°C 
at 13,000 rpm. Shearing is performed to create chromatin 
fragments of 200-1000bp, which was confirmed by gel 
electrophoresis following DNA isolation of 50 μl of the 
500 μl sample with 30 minutes incubation with 100 μl 
H2O, 6 μl 5 M NaCl and 2 μl RNAse A (10 mg/ml) at 37°C 
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and a subsequent 2 hour incubation with adding of 2 μl 
proteinase K (20 mg/ml) at 65°C. The DNA was purified 
with the Roche high pure PCR purification kit.
Chromatin immunoprecipitation
Prior to precipitation, chromatin was precleared 
with negative control IgG from rabbit serum for two 
hours, followed by incubation with protein-G magnetic 
beads (Invitrogen Dynal AS) for 1 hour, after which the 
beads were removed and discarded. A 10 μl input sample 
was set aside and ChIP was performed overnight with 
2.5 mg H3K9Ac (ab4441, Abcam, Cambridge, UK) 
or H3K27me3 (ab6002, Abcam) antibodies, as well 
as a negative control IgG from rabbit serum, followed 
by 2 hours incubation with protein-G magnetic beads. 
Subsequently the beads are sequestered by a magnet and 
the supernatant removed. The beads were washed 3 times 
with a low salt buffer (20 mM Tris-HCl (pH 8.0) + 2 mM 
EDTA + 1 % Triton X-100 + 150 mM NaCl), 1 time a high 
salt wash (20 mM Tris-HCl (pH 8.0) + 2 mM EDTA + 1 
% Triton X-100 + 0.1% SDS + 500 mM NaCl) and 1 time 
a LiCl wash (10 mM Tris-HCl (pH 8.0) + 1 mM EDTA 
+ 0.25M LiCl + 0.5% IGEPAL + 0.5% Deoxycholate 
(sodium salt)) for 5 minutes at 4°C. After a subsequent 
TE buffer wash, 150 μl elution buffer (25 mM Tris-HCl 
(pH 7.5) + 10 mM EDTA + 0.5% SDS) was added to 
the beads as well as the input sample, the beads were 
incubated at 65°C for 30 minutes. The eluted chromatin 
was then transferred to clean Eppendorf tubes and together 
with the input samples incubated overnight with 6 μl 5 M 
NaCl and 2 μl Proteinase K (20 mg/ml). The precipitated 
DNA and input DNA was isolated by Roche high pure 
PCR purification kit and eluted in 50 μl H2O.
Enrichment of the sst2 promoter was analyzed at 
three positions, primer sequences are described in Table 1. 
Furthermore negative and positive controls were analyzed 
for both histone marks (data not shown). Q-PCR was 
performed with Roche Fast start Universal SYBR green 
master mix (Rox) according to protocol. The percentage 
recovery was calculated by 100% × E^(CTinput-adjusted – CtIP), 
with E being the efficiency coefficient of the primers. The 
correction factor for the adjusted CT for input DNA was 
calculated by E^X =50, with X being the correction factor. 
For the primer sets -2, -1 and tss, the efficiency factors 
were 1.9, 2.2, 1.9, respectively.
Statistics
In order to stabilize the variance, the data was 
log transformed before statistical analysis. For the 
comparison of treatment means, the Tukey post hoc 
test method was applied. All data were analyzed using 
GraphPad (Prism 5, La Jolla, CA, USA). P values <0.05 
were considered significant. To compare the cAMP data, 
we performed an F-test.
ACKNOWLEDGMENTS
This research was financially supported by Erasmus 
MC Vriendenfonds and by a donation from Mr. and 
Mrs. Westra. The authors would like to thank Ing. J.H. 
Havermans and Dr. K. Yacqub-Usman for their advice 
concerning performing chromatin immunoprecipitation.
CONFLICTS OF INTEREST
LH has received investigator-initiated research 
grants from Ipsen and Novartis. RAF has received 
research grants from Novartis. WWH is in the advisory 
board of- and has received research support from Novartis 
and Ipsen.
REFERENCES
1. de Herder WW, van der Lely AJ, Lamberts SW. 
Somatostatin analogue treatment of neuroendocrine 
tumours. Postgraduate medical journal. 1996; 72:403-408.
2. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth 
P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, 
Harder J, Arnold C, Gress T, Arnold R. Placebo-controlled, 
double-blind, prospective, randomized study on the effect 
of octreotide LAR in the control of tumor growth in 
patients with metastatic neuroendocrine midgut tumors: a 
report from the PROMID Study Group. J Clin Oncol. 2009; 
27:4656-4663.
3. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, 
Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, 
Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski 
P. Lanreotide in metastatic enteropancreatic neuroendocrine 
tumors. N Engl J Med. 2014; 371:224-233.
4. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. 
Current opinion in oncology. 2012; 24:46-55.
5. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, 
van Essen M, Teunissen JJ, Krenning EP. Peptide receptor 
radionuclide therapy in patients with gastroenteropancreatic 
neuroendocrine tumors. Semin Nucl Med. 2010; 40:78-88.
6. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder 
WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: 
Radionuclide therapy in neuroendocrine tumors. Eur J 
Endocrinol. 2015; 172:R1-8.
7. Veenstra MJ, de Herder WW, Feelders RA, Hofland 
LJ. Targeting the somatostatin receptor in pituitary and 
neuroendocrine tumors. Expert Opin Ther Targets. 2013; 
17:1329-1343.
8. Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi 
H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, 
Watanabe M, Koizumi W. Clinicopathologic characteristics 
of pancreatic neuroendocrine tumors and relation of 
somatostatin receptor type 2A to outcomes. Cancer. 2013; 
119:4094-4102.
Oncotarget12www.impactjournals.com/oncotarget
9. Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, 
Souque A, Susini C, Cordelier P, Buscail L. Identification of 
an upstream promoter of the human somatostatin receptor, 
hSSTR2, which is controlled by epigenetic modifications. 
Endocrinology. 2008; 149:3137-3147.
10. Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM. 
Genomic structure and transcriptional regulation of the 
human somatostatin receptor type 2. Mol Cell Endocrinol. 
1999; 157:75-85.
11. Sun L, Qian Q, Sun G, Mackey LV, Fuselier JA, Coy DH, 
Yu CY. Valproic acid induces NET cell growth arrest 
and enhances tumor suppression of the receptor-targeted 
peptide-drug conjugate via activating somatostatin receptor 
type II. Journal of drug targeting. 2015:1-9.
12. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, 
Haymart M, Kunnimalaiyaan M, Chen H. Valproic acid 
activates notch-1 signaling and regulates the neuroendocrine 
phenotype in carcinoid cancer cells. The oncologist. 2007; 
12:942-951.
13. Evers BM, Ishizuka J, Townsend CM, Jr., Thompson JC. 
The human carcinoid cell line, BON. A model system for 
the study of carcinoid tumors. Ann N Y Acad Sci. 1994; 
733:393-406.
14. Kaku M, Nishiyama T, Yagawa K, Abe M. Establishment 
of a carcinoembryonic antigen-producing cell line from 
human pancreatic carcinoma. Gan. 1980; 71:596-601.
15. Vandamme T, Peeters M, Dogan F, Pauwels P, Van Assche 
E, Beyens M, Mortier G, Vandeweyer G, de Herder W, 
Van Camp G, Hofland LJ, Op de Beeck K. Whole-exome 
characterization of pancreatic neuroendocrine tumor 
cell lines BON-1 and QGP-1. J Mol Endocrinol. 2015; 
54:137-147.
16. Nakayama Y, Wada R, Yajima N, Hakamada K, Yagihashi 
S. Profiling of somatostatin receptor subtype expression by 
quantitative PCR and correlation with clinicopathological 
features in pancreatic endocrine tumors. Pancreas. 2010; 
39:1147-1154.
17. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi 
S, Helboe L, Schindler M, Cole SL, Bussolati G. 
Expression of somatostatin receptor types 1-5 in 81 cases 
of gastrointestinal and pancreatic endocrine tumors. A 
correlative immunohistochemical and reverse-transcriptase 
polymerase chain reaction analysis. Virchows Arch. 2002; 
440:461-475.
18. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert 
A, Jaquet P, Ruszniewski P, Barlier A. The analysis of 
quantitative expression of somatostatin and dopamine 
receptors in gastro-entero-pancreatic tumours opens new 
therapeutic strategies. Eur J Endocrinol. 2006; 155:849-857.
19. Mussig K, Oksuz MO, Dudziak K, Ueberberg B, Wehrmann 
M, Horger M, Schulz S, Haring HU, Pfannenberg C, Bares R, 
Gallwitz B, Petersenn S. Association of somatostatin receptor 
2 immunohistochemical expression with [111In]-DTPA 
octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in 
neuroendocrine tumors. Horm Metab Res. 2010; 42:599-606.
20. Portela A, Esteller M. Epigenetic modifications and human 
disease. Nat Biotechnol. 2010; 28:1057-1068.
21. Kulis M, Esteller M. DNA methylation and cancer. Adv 
Genet. 2010; 70:27-56.
22. Sawan C, Herceg Z. Histone modifications and cancer. Adv 
Genet. 2010; 70:57-85.
23. Karahoca M, Momparler RL. Pharmacokinetic and 
pharmacodynamic analysis of 5-aza-2'-deoxycytidine 
(decitabine) in the design of its dose-schedule for cancer 
therapy. Clin Epigenetics. 2013; 5:3.
24. Momparler RL. Epigenetic therapy of cancer with 5-aza-
2'-deoxycytidine (decitabine). Semin Oncol. 2005; 
32:443-451.
25. Cincarova L, Zdrahal Z, Fajkus J. New perspectives 
of valproic acid in clinical practice. Expert opinion on 
investigational drugs. 2013; 22:1535-1547.
26. Silva MF, Aires CC, Luis PB, Ruiter JP, L IJ, Duran 
M, Wanders RJ, Tavares de Almeida I. Valproic acid 
metabolism and its effects on mitochondrial fatty acid 
oxidation: a review. Journal of inherited metabolic disease. 
2008; 31:205-216.
27. Gatto F, Hofland LJ. The role of somatostatin and dopamine 
D2 receptors in endocrine tumors. Endocr Relat Cancer. 
2011; 18:R233-251.
28. Ramirez JL, Gracia-Navarro F, Garcia-Navarro S, 
Torronteras R, Malagon MM, Castano JP. Somatostatin 
stimulates GH secretion in two porcine somatotrope 
subpopulations through a cAMP-dependent pathway. 
Endocrinology. 2002; 143:889-897.
29. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with 
'epigenetic' drugs: an update. Mol Oncol. 2012; 6:657-682.
30. Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic 
treatment of solid tumours: a review of clinical trials. Clin 
Epigenetics. 2015; 7:127.
31. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder 
WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, 
Feelders R, van der Lely AJ, Beckers A, Lamberts SW. The 
novel somatostatin analog SOM230 is a potent inhibitor 
of hormone release by growth hormone- and prolactin-
secreting pituitary adenomas in vitro. J Clin Endocrinol 
Metab. 2004; 89:1577-1585.
32. Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk 
J, Mooy DM, Lichtenauer-Kaligis EG, Colao A, Bogers 
AJ, Lombardi G, Lamberts SW, Hofland LJ. In vitro 
characterization of somatostatin receptors in the human 
thymus and effects of somatostatin and octreotide on 
cultured thymic epithelial cells. Endocrinology. 1999; 
140:373-380.
33. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk 
J, Breeman WA, Lamberts SW. Internalization of 
the radioiodinated somatostatin analog [125I-Tyr3]
octreotide by mouse and human pituitary tumor cells: 
increase by unlabeled octreotide. Endocrinology. 1995; 
136:3698-3706.
